|
1）Zhang D, Loughran TP Jr. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program. 2012; 652-9
|
|
|
|
2）Zhang R, Shah MV, Yang J, et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A. 2008; 105: 16308-13
|
|
|
|
|
3）Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366: 1905-13
|
|
|
|
|
|
4）Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012; 120: 3048-57
|
|
|
|
|
|
5）Teramo A, Gattazzo C, Passeri F, et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood. 2013; 121: 3843-54
|
|
|
|
|
|
6）Chan WC, Foucar K, Morice WG, et al. T-cell large granular lymphocytic leukaemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. p.272-3
|
|
|
|
|
|
7）Villamor N, Morice WG, Chan WC, et al. Chronic lymphoproliferative disorders of NK cells. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. p.274-5
|
|
|
|
|
|
8）Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993; 82: 1-14
|
|
|
|
|
|
9）Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006; 11: 263-73
|
|
|
|
|
|
10）Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004; 117: 1281-3
|
|
|
|
|
|
11）Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001; 107: 351-62
|
|
|
|
|
|
12）Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999; 98: 295-303
|
|
|
|
|
|
13）Oshimi K, Shinkai Y, Okumura K, et al. Perforin gene expression in granular lymphocyte proliferative disorders. Blood. 1990; 75: 704-8
|
|
|
|
|
|
14）Lamy T, Liu JH, Landowski TH, et al. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998; 92: 4771-7
|
|
|
|
|
|
15）Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7: 41-51
|
|
|
|
|
|
16）Rajala HL, Eldfors S, Kuusanmäki H, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121: 4541-50
|
|
|
|
|
|
17）Kang K, Robinson GW, Hennighausen L. Comprehensive meta-analysis of Signal Transducers and Activators of Transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics. 2013; 14: 4
|
|
|
|
|
|
18）Fehniger TA, Suzuki K, VanDeusen JB, et al. Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis. 2001; 27: 223-30
|
|
|
|
|
|
19）Mishra A, Liu S, Sams GH, et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell. 2012; 22: 645-55
|
|
|
|
|
|
20）Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003; 170: 3263-72
|
|
|
|
|
|
21）Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997; 89: 201-11
|
|
|
|
|
|
22）Hayakawa F, Sugimoto K, Kurahashi S, et al. A novel STAT3 inhibitor OPB-31121 induces tumor-specific growth inhibition in a wide range of hematopoietic malignancies without growth suppression of normal hematopoietic cells. In: Program and abstracts of the 53rd American Society of Hematology annual meeting and exposition, San Diego, December 10-3, 2011. Abstract
|
|
|
|
|
|
23）Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117: 3421-9
|
|
|
|
|
|
24）Nelson EA, Walker SR, Xiang M, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer. 2012; 3: 503-11
|
|
|
|
|